Key result
Parecoxib matches ketorolac for post-surgical pain reduction while sparing opioids and causing fewer gastroduodenal ulcers.
Why the study?
Does parecoxib reduce pain following surgery compared to ketorolac or placebo?
Does parecoxib reduce pain following surgery compared to ketorolac or placebo?
Answers are grounded in this paper and cite their sources.
Parecoxib is an effective parenteral COX-2 inhibitor for post-surgical pain management with a favorable gastrointestinal and hematologic safety profile compared to traditional NSAIDs like ketorolac.
Parecoxib (Dynastat) is a parenteral cyclooxygenase-2 inhibitor available in Europe. Clinical trials have reported a benefit in reducing pain following oral, orthopedic, gynecologic and cardiac surgeries. The overall efficacy was dose-related and similar to ketorolac (Toradol). Several trials reported an opioid-sparing effect with parecoxib. No trials have reported significantly fewer opioid-related gastrointestinal side effects (e.g., nausea, vomiting, constipation and intestinal ileus) when opioids were administered with parecoxib versus placebo. Gastroduodenal ulcers, gastric ulcers and duodenal ulcers or erosions were less common with parecoxib than ketorolac. Parecoxib does not affect platelet aggregation, interfere with the antiplatelet affect of aspirin, affect prothrombin and partial thromboplastin time or platelet counts when administered with heparin.
No takes yet. Share an insight, caveat, or question.
Dalpiaz et al. (2004) conducted a review in Postoperative pain. Parecoxib vs. Ketorolac and placebo was evaluated on Pain reduction. Parecoxib provided dose-related pain reduction similar to ketorolac following surgery, with an opioid-sparing effect and fewer gastroduodenal ulcers than ketorolac.
Synapse has enriched 10 related papers. Consider them for comparative context: